Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy
Roodink, I.; van Erp, M.; Li, A.; Potter, S.; van Duijnhoven, S. M. J.; Kuipers, A. J.; Kazemier, B.; van Geffen, E.; Hemrika, W.; Berkeveld, B.; Sonnemans, G.; de Vries, B. S.; Boers, B.; Smits, M.; Meurs, S.; de Pooter, M.; Thom, A.; Duplantis, B. N.; Romijn, R. A.; Houser, J. S.; Bath, J.; Abdiche, Y. N.
Show abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an ongoing global human health crisis and will likely become endemic, requiring novel sustainable therapeutic strategies. We report on the discovery of a fully human multi-antibody cocktail (TATX-03) targeting diversified non-overlapping epitopes on the SARS-CoV-2 spike protein that suppressed replication-competent viral titers to undetectable levels in the lungs of SARS-CoV-2 challenged hamsters upon both prophylactic and therapeutic administration. While monotherapy with two of the individual cocktail components also showed clear in vivo protection, neither recapitulated the efficacy of TATX-03. This synergistic effect was further supported by examining in vivo efficacy of these individual antibodies and corresponding combination therapy at a lower dose. Furthermore, in vitro screenings using VSV-particles pseudo-typed with spike proteins representing the SARS-CoV-2 variants of concern Alpha, Beta, and Delta showed that TATX-03 maintained its neutralization potency. These results merit further development of TATX-03 as a potential therapy for SARS-CoV-2 infection with resistance to mutagenic escape.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin 96%
- SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 96%
- A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo 96%
Similar papers in this journal
- A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy 97%
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19 97%
- Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies 96%
Similar papers in this journal
- Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies 97%
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination 96%
- Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike 96%
Similar papers in this journal
- Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses 96%
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 96%
- Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 96%
Similar papers in this journal
- Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses 96%
- A Remarkable Genetic Shift in a Transmitted/Founder Virus Broadens Antibody Responses Against HIV-1 96%
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.